<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694300</url>
  </required_header>
  <id_info>
    <org_study_id>844440</org_study_id>
    <secondary_id>IIR</secondary_id>
    <nct_id>NCT04694300</nct_id>
  </id_info>
  <brief_title>OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients</brief_title>
  <official_title>Demonstration of OTC Naproxen Sodium's (Aleve's) Anti-inflammatory Action in Dental Implant Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hersh, Elliot V., DMD, MS, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hersh, Elliot V., DMD, MS, PhD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind pilot study will evaluate the anti-inflammatory and analgesic effects of an&#xD;
      over-the-counter (OTC) regimen of naproxen sodium versus acetaminophen in patients receiving&#xD;
      one or two (adjacent) dental implants. It will also confirm that naproxen sodium in the OTC&#xD;
      dosage range is a good alternative to immediate-release opioid formulations, which are&#xD;
      subject to misuse, abuse and diversion in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placement of dental implants is a frequently performed outpatient surgical procedure, with&#xD;
      United States dentists currently placing implants in approximately 500,000 patients per&#xD;
      year.This procedure has become the gold standard for replacing missing teeth due to its high&#xD;
      level of predictability and patient acceptance, with long-term success rates greater than&#xD;
      95%. Thus, the number of patients opting for this procedure over dentures and fixed bridges&#xD;
      continues to increase. In the period between 1999 and 2000 only 0.7% of the USA population&#xD;
      had missing teeth with implants in contrast to 5.7% between 2015 and 2016 It is estimated&#xD;
      that by 2026, if the current pace of dental implant placement continues, approximately 17% of&#xD;
      the population will have dental implants.&#xD;
&#xD;
      Dental implant surgery involves the incision of gingival tissue to expose the underlying&#xD;
      bone, followed by the creation of a precise bony cavity where the implant will be placed&#xD;
      using a specialized surgical drill, and lastly the screwing of the implant into bone using a&#xD;
      specialized handpiece Thus, it is not surprising that post-surgical pain is a common sequela&#xD;
      following dental implant surgery. Patients often experience post-surgical pain for several&#xD;
      days after the placement of one to three dental implants, but at a pain intensity level that&#xD;
      is generally less than that of dental impaction surgery. This post-surgical pain is&#xD;
      inflammatory in nature; thus, NSAIDs have demonstrated efficacy and are the preferred&#xD;
      analgesics in this patient population. Postoperative administration of intranasal ketorolac&#xD;
      (SPRIX®) and oral acetaminophen 325 mg plus codeine 30 mg have both demonstrated efficacy.&#xD;
&#xD;
      The soft tissue and bony trauma associated with dental implant surgery upregulates&#xD;
      inflammatory mediators both locally and systemically. Elevated levels of interleukin (IL)-6,&#xD;
      IL-8, and macrophage inflammatory protein (MIP)-1β have been observed in gingival crevicular&#xD;
      fluid (GCF) from the implant site and the adjacent teeth one week after surgery.&#xD;
      Prostaglandin E2 has been measured in the GCF of teeth surrounding implant sites employing&#xD;
      similar methodology. Additionally, standard periodontal flap and bony recontouring surgery,&#xD;
      which shares many similarities to dental implant surgery, induces an upregulation in&#xD;
      immunoreactive prostaglandin E2 and leukotriene B4 levels at the surgical site. Dental&#xD;
      implant surgery also increases cytokine levels in plasma, indicative of a systemic&#xD;
      inflammatory response. Thus, in addition to being a model to study the efficacy and&#xD;
      tolerability of OTC analgesics, dental implant surgery also appears to be an excellent model&#xD;
      to study the anti-inflammatory properties of NSAIDs such as naproxen sodium.&#xD;
&#xD;
      Therefore, the investigators propose to initiate a double-blind, pilot study to evaluate the&#xD;
      anti-inflammatory and analgesic effects of an OTC regimen of naproxen sodium versus&#xD;
      acetaminophen in dental implant surgery patients. Notably, the vast majority of these&#xD;
      patients are over the age of 45, a patient demographic that is rarely captured in&#xD;
      postsurgical dental pain studies. Compared to dental impaction surgery patients, implant&#xD;
      surgery patients possess more comorbidities such as hypertension, hyperlipidemia and&#xD;
      hyperglycemia Thus, while dental impaction patients are typically on few if any drugs,&#xD;
      polypharmacy is more of the norm in dental implant surgery patients. Performing a controlled&#xD;
      study with OTC naproxen sodium in this population will provide the opportunity to confirm&#xD;
      that its short-term use is generally safe and effective in these older, more medically&#xD;
      complex patients. It will also confirm that naproxen sodium in the OTC dosage range is a good&#xD;
      alternative to immediate-release opioid formulations, which are subject to misuse, abuse and&#xD;
      diversion in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2021</start_date>
  <completion_date type="Anticipated">April 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind, randomized, active-controlled, two arms</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Administration of naproxen or acetaminophen will be masked by over-encapsulation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prostaglandin E2 concentrations employing liquid chromatography/mass spectrometry</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Assessment of PGE2 in urine and gingival crevicular fluid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor concentrations employing ELISA</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Assessment of TNF levels in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin 6 concentrations employing ELISA</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Assessment of IL-6 levels in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity scores on numeric pain intensity scale</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Pain intensity scores where 0 = no pain and 10 = worst possible pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue analgesic use</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Need for opioid rescue medication (tramadol) in addition to blinded study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour area under the pain intensity curve (SPI24)</measure>
    <time_frame>1 day</time_frame>
    <description>Derived from 0-10 numeric pain intensity scale (0= no pain, 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX-2 activity</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>COX-2 activity will be measured ex vivo using a whole blood assay and in vivo by quantifying concentrations of prostaglandin metabolites in urine and gingival crevicular fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX-1 activity</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>COX-1 activity will be measured ex vivo using a whole blood assay and in vivo by quantifying concentrations of prostaglandin metabolites in urine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osseointegrated Dental Implantation</condition>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Naproxen sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen sodium 440 mg followed by naproxen sodium 220 mg q 8h (max 660 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetaminophen 1000 mg followed by acetaminophen 1000 mg q 6h (max 3000 mg/day according to Tylenol package insert)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.&#xD;
Then 220 mg every 8 hours for the next two days.</description>
    <arm_group_label>Naproxen sodium</arm_group_label>
    <other_name>Aleve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <other_name>Extra Strength Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>50 mg by mouth every 6 hours as needed for pain</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_label>Naproxen sodium</arm_group_label>
    <other_name>Ultram</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject requires surgical placement of one or two (adjacent) dental implants&#xD;
&#xD;
          -  Ability to read and sign informed consent&#xD;
&#xD;
          -  Males and females for 18-75 years of age&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Negative urine drug screen&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Advanced periodontal disease (&gt;20% Clinical Attachment Loss &gt;20% radiographic bone&#xD;
             loss)&#xD;
&#xD;
          -  History of bisphosphonate usage&#xD;
&#xD;
          -  Medical history or medical condition that makes any of the study medications (naproxen&#xD;
             sodium, acetaminophen, tramadol, etc.) inappropriate treatment options including any&#xD;
             scheduled or recent cardiac procedures (within 6 months), a history of GI ulcers,&#xD;
             liver or kidney disease, and anticoagulant or lithium intake.&#xD;
&#xD;
          -  History of an allergic reaction to any pain reliever/fever reducer&#xD;
&#xD;
          -  Contraindication to opioid use&#xD;
&#xD;
          -  Positive urine drug screen for drugs of abuse unless on stable doses of a&#xD;
             non-analgesic drug for a legitimate medical purpose&#xD;
&#xD;
          -  Pregnancy - A urine pregnancy test will be performed immediately before the scheduled&#xD;
             surgery on all women of child-bearing potential&#xD;
&#xD;
          -  Local or systemic diseases that affects wound healing and inflammatory biomarkers&#xD;
             (diabetes, autoimmune (rheumatoid arthritis), or inflammatory disorders -&#xD;
             osteoarthritis is allowed).&#xD;
&#xD;
          -  Smokers on this pilot study because it can affect levels of inflammatory biomarkers -&#xD;
             a urine cotinine test will be performed immediately prior to the scheduled surgery on&#xD;
             all subjects even if participant denies smoking history&#xD;
&#xD;
          -  History of systemic steroid use over 2 weeks within last 2 years.&#xD;
&#xD;
          -  Poor oral hygiene on a non-compliant individual.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot V Hersh, DMD, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katherine N Theken, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania School of Dental Medicine and Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elliot V Hersh, DMD, MS, PhD</last_name>
    <phone>215-898-9686</phone>
    <email>evhersh@upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine N Theken, PharmD, PhD</last_name>
    <phone>215-573-9592</phone>
    <email>ktheken@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania School of Dental Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliot V Hersh, DMD, MS, PhD</last_name>
      <phone>215-898-9686</phone>
      <email>evhersh@upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Secreto, EMT, CCRC</last_name>
      <phone>215-746-8871</phone>
      <email>secreto@upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elliot V Hersh, DMD, MS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Korostoff, DMD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Cheng Chang, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Fiorellini, DMD, DScD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Yoo, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine N Theken, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Mitchell, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf</url>
    <description>eference ID 4028238 - FDA. Highlights of prescribing information for Naprosyn®, EC-Naprosyn® and Anaprox®</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020204Orig1s052lbl.pdf</url>
    <description>Aleve Product Information</description>
  </link>
  <link>
    <url>http://brandongaille.com/17-dental-implant-industry-statistics-and-trends/</url>
    <description>17 Dental Implant Industry Statistics and Trends.</description>
  </link>
  <reference>
    <citation>Moore PA, Hersh EV. Combining ibuprofen and acetaminophen for acute pain management after third-molar extractions: translating clinical research to dental practice. J Am Dent Assoc. 2013 Aug;144(8):898-908. Review.</citation>
    <PMID>23904576</PMID>
  </reference>
  <reference>
    <citation>Hersh EV, Moore PA, Grosser T, Polomano RC, Farrar JT, Saraghi M, Juska SA, Mitchell CH, Theken KN. Nonsteroidal Anti-Inflammatory Drugs and Opioids in Postsurgical Dental Pain. J Dent Res. 2020 Jul;99(7):777-786. doi: 10.1177/0022034520914254. Epub 2020 Apr 14.</citation>
    <PMID>32286125</PMID>
  </reference>
  <reference>
    <citation>Deeb GR, Deeb JG, Agarwal V, Laskin DM. Use of transalveolar sutures to maintain vestibular depth and manipulate keratinized tissue following alveolar ridge reduction and implant placement for mandibular prosthesis. J Oral Maxillofac Surg. 2015 Jan;73(1):48-52. doi: 10.1016/j.joms.2014.07.022. Epub 2014 Jul 30.</citation>
    <PMID>25315314</PMID>
  </reference>
  <reference>
    <citation>Schmitt A, Zarb GA. The longitudinal clinical effectiveness of osseointegrated dental implants for single-tooth replacement. Int J Prosthodont. 1993 Mar-Apr;6(2):197-202.</citation>
    <PMID>8329098</PMID>
  </reference>
  <reference>
    <citation>Zarb GA, Schmitt A. The longitudinal clinical effectiveness of osseointegrated dental implants in posterior partially edentulous patients. Int J Prosthodont. 1993 Mar-Apr;6(2):189-96.</citation>
    <PMID>8329097</PMID>
  </reference>
  <reference>
    <citation>Elani HW, Starr JR, Da Silva JD, Gallucci GO. Trends in Dental Implant Use in the U.S., 1999-2016, and Projections to 2026. J Dent Res. 2018 Dec;97(13):1424-1430. doi: 10.1177/0022034518792567. Epub 2018 Aug 3.</citation>
    <PMID>30075090</PMID>
  </reference>
  <reference>
    <citation>Bockow R, Korostoff J, Pinto A, Hutcheson M, Secreto SA, Bodner L, Hersh EV. Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac. Compend Contin Educ Dent. 2013 Sep;34(8):570-6.</citation>
    <PMID>24564610</PMID>
  </reference>
  <reference>
    <citation>Alissa R, Sakka S, Oliver R, Horner K, Esposito M, Worthington HV, Coulthard P. Influence of ibuprofen on bone healing around dental implants: a randomised double-blind placebo-controlled clinical study. Eur J Oral Implantol. 2009 Autumn;2(3):185-99.</citation>
    <PMID>20467629</PMID>
  </reference>
  <reference>
    <citation>Hashem AA, Claffey NM, O'Connell B. Pain and anxiety following the placement of dental implants. Int J Oral Maxillofac Implants. 2006 Nov-Dec;21(6):943-50.</citation>
    <PMID>17190305</PMID>
  </reference>
  <reference>
    <citation>Al-Khabbaz AK, Griffin TJ, Al-Shammari KF. Assessment of pain associated with the surgical placement of dental implants. J Periodontol. 2007 Feb;78(2):239-46.</citation>
    <PMID>17274712</PMID>
  </reference>
  <reference>
    <citation>Samieirad S, Afrasiabi H, Tohidi E, Qolizade M, Shaban B, Hashemipour MA, Doaltian Shirvan I. Evaluation of caffeine versus codeine for pain and swelling management after implant surgeries: A triple blind clinical trial. J Craniomaxillofac Surg. 2017 Oct;45(10):1614-1621. doi: 10.1016/j.jcms.2017.06.014. Epub 2017 Jul 5.</citation>
    <PMID>28864284</PMID>
  </reference>
  <reference>
    <citation>Emecen-Huja P, Eubank TD, Shapiro V, Yildiz V, Tatakis DN, Leblebicioglu B. Peri-implant versus periodontal wound healing. J Clin Periodontol. 2013 Aug;40(8):816-24. doi: 10.1111/jcpe.12127. Epub 2013 Jun 18.</citation>
    <PMID>23772674</PMID>
  </reference>
  <reference>
    <citation>Aboyoussef H, Carter C, Jandinski JJ, Panagakos FS. Detection of prostaglandin E2 and matrix metalloproteinases in implant crevicular fluid. Int J Oral Maxillofac Implants. 1998 Sep-Oct;13(5):689-96.</citation>
    <PMID>9796154</PMID>
  </reference>
  <reference>
    <citation>O'Brien TP, Roszkowski MT, Wolff LF, Hinrichs JE, Hargreaves KM. Effect of a non-steroidal anti-inflammatory drug on tissue levels of immunoreactive prostaglandin E2, immunoreactive leukotriene, and pain after periodontal surgery. J Periodontol. 1996 Dec;67(12):1307-16.</citation>
    <PMID>8997678</PMID>
  </reference>
  <reference>
    <citation>Li S, Yang Y, Yu C, Yao Y, Wu Y, Qian L, Cheung CW. Dexmedetomidine Analgesia Effects in Patients Undergoing Dental Implant Surgery and Its Impact on Postoperative Inflammatory and Oxidative Stress. Oxid Med Cell Longev. 2015;2015:186736. doi: 10.1155/2015/186736. Epub 2015 Jun 15.</citation>
    <PMID>26171113</PMID>
  </reference>
  <reference>
    <citation>Pietruski JK, Pietruska MD, Stokowska W, Pattarelli GM. Serum levels of interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8) in patients treated with dental implants. Rocz Akad Med Bialymst. 2001;46:28-37.</citation>
    <PMID>11780571</PMID>
  </reference>
  <reference>
    <citation>Aghaloo T, Pi-Anfruns J, Moshaverinia A, Sim D, Grogan T, Hadaya D. The Effects of Systemic Diseases and Medications on Implant Osseointegration: A Systematic Review. Int J Oral Maxillofac Implants. 2019 Suppl;34:s35-s49. doi: 10.11607/jomi.19suppl.g3.</citation>
    <PMID>31116832</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Naproxen sodium</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Postsurgical dental pain</keyword>
  <keyword>Prostaglandins</keyword>
  <keyword>Tumor Necrosis Factor</keyword>
  <keyword>Interleukins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared. This is a pilot, exploratory study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

